Pre-made Tenatumomab benchmark antibody ( Whole mAb Radiolabelled, anti-TNC therapeutic antibody, Anti-150-225/DFNA56/GMEM/GP/HXB/JI/TN/TN-C Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Tenatumomab biosimilar, Whole mAb Radiolabelled, Anti-TNC Antibody: Anti-150-225/DFNA56/GMEM/GP/HXB/JI/TN/TN-C therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tenatumomab is a monoclonal antibody designed for the treatment of cancer.
| Products Name (INN Index) | Pre-Made Tenatumomab biosimilar, Whole mAb Radiolabelled, Anti-TNC Antibody: Anti-150-225/DFNA56/GMEM/GP/HXB/JI/TN/TN-C therapeutic antibody |
|---|---|
| INN Name | Tenatumomab |
| Target | TNC |
| Format | Whole mAb Radiolabelled |
| Derivation | Mouse |
| Species Reactivity | Human |
| CH1 Isotype | IgG2b |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2007 |
| Year Recommended | 2008 |
| Companies | sigma-tau SpA |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Cancer |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | TNC |
| Package |
